Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance

Hims & Hers' stock plummets 15% after reporting a first-quarter loss and weak earnings guidance. The company had previously reached a deal with Novo Nordisk to sell the GLP-1 weight loss drug Wegovy on its platform. This partnership was announced in March.